Disease-specific iPS cells and PRSS1
Introduction
Induced pluripotent stem cell (iPSC) technology enables reprogramming of multipotent undifferentiated cells that can be used for the generation of disease-specific germline mutations harboring somatic cells, as well as normal healthy cells. Therefore, disease-specific iPSCs are regarded as important tools to monitor disease processes, to explore drug screening and discovery, and to elucidate the pathophysiology of human diseases (Bellin et al., 2012; Maehr et al., 2009 ). Previous studies have used disease-specific iPSCs from patients with hereditary disorders to clarify the pathogenesis of muscle dystrophy (Shoji et al., 2015) and fibrodysplasia ossificans progressive (Matsumoto et al., 2013) .
Although the use of iPSCs was successful in the reproduction of the phenotypes of those diseases, its application for pancreatic diseases, such as pancreatitis and diabetes (Borowiak and Melton, 2009) , and some other diseases of the kidney (Mae and Osafune, 2015) and liver (Sakiyama et al., 2017) remains to be successfully performed, presumably due to the difficulty of cell differentiation in vivo and the complexity of the organ structures. In order to reproduce the diseases that are derived from tissues, in which induction of differentiation is difficult, it is undoubtedly necessary to improve the efficiency of differentiation induction and to reconstruct the complexity of tissues in a model.
The blastocyst complementation (BC) method has been reported to be applicable for the construction of pancreatic tissues. Mice without the knockout allele of the pancreatic and duodenal homeobox 1 (Pdx1) gene, which is a critical transcription factor that determines the fate of pancreatic endocrine and exocrine differentiation, have been reported to manifest with lethal phenotypes immediately after birth due to a defective formation of the pancreas, and injection of wild-type embryonal stem (ES) cells in a knockout blastocyst of the Pdx1 gene rescued the mice completely (Offield et al., 1996; Kobayashi et al., 2010) . In a previous study, the BC method was applied for pancreatic formation in an intercross species condition (i.e., rats to mice or vice versa) (Kobayashi et al., 2010) . This indicated the possible human application of this regenerative medicine technology in the future.
Although the BC method using disease-specific pluripotent stem cells had been suggested to reproduce hereditary diseases in vivo, its application on the study of hereditary diseases has been reported by only a few. In the present study, we (Whitcomb et al., 1996) . In this study, we established the ESCs harboring the Prss1 mutation and successfully performed the BC method to reproduce the HP phenotype of in mice.
Results

Establishment of a disease-specific iPS model using mouse embryonic stem cell
Mutation in the PRSS1 gene is known as one of the most common causes of HP (Whitcomb et al., 1996) . We examined the mutated gene, the major mutation residues, and the mutation rate in HP. As a result, PRSS1 was the most frequently mutated gene in HP (Table S1 ). In general, translation of the PRSS1 leads to the production of the precursor of trypsinogen, which is cleaved off from the region of its signal peptide and the trypsinogen-activating peptide, resulting in the activation of trypsin; on the other hand, cleavage of activated trypsin causes inactivation. Substitution of amino acids due to mutations, which play a role in the activation of the trypsinogen precursor or the activated trypsin, was reported to result in pancreatitis (Gorry et al., 1997) . Moreover, the substitution of alanine to valine at position 16 (A16V) was reported to result in the abnormal processing of the trypsinogen precursor; whereas mutations of the D16A, D22G, and N29I, or N29T caused abnormalities in the activation of trypsin (Raphael and Willingham, 2016) . Mutations in the R122H or R122C have been known to interfere with the inactivation of activated trypsin (Raphael and Willingham, 2016) . The N29I was observed as the most common mutated gene in HP (Gorry et al., 1997) , suggesting its critical role in HP. However, the precise mechanism for disease development remains to be elucidated.
To establish the disease-specific iPSCs that correspond to HP in an animal model, we compared the PRSS1 genes in mice and humans and found 95% similarity and 76% identical amino acid sequences (Figures 1A), indicating conservation of the peptide sequence of the PRSS1 protein among the species.
On the other hand, the 29th amino acid residue of PRSS1, which causes HP, was different between human (H) and mouse (T). We created both PRSS1 structures and investigated for changes after mutation of the 29th amino acid residue. As a result, each structure was destabilized by the mutation in the 29th amino acid residue ( Figure 1B) . Moreover, the phenotype of HP might depend on the original residue if the human PRSS1 mutation is mimicked in a mouse model. Therefore, we created two three-dimensional (3D) structures by exchanging the 29th residue in the PRSS1 of human and mouse and comparing these with the structure of each wild PRSS1. As a result, none of the residues affected the original protein structure, suggesting that changing the structure by mutating to isoleucine did not depend on the original residue ( Figure 1C ). We then designed the guide RNA for the introduction of T29I mutation by CRISPR/CAS9 technology ( Figure 2A ). By introduction of the guide RNA into mouse ESCs, we established PRSS1-mutant ESCs, the sequence of which verified introduction of the mutation in the ESCs (PRSS1 T29I ESCs; Figure 2B ).
The PRSS1 T29I ESCs and wild-type ESCs were cultured and maintained successfully in an undifferentiated state in a medium that contained leukemia inhibitory factor (LIF) ( Figure 2C ).
PRSS1
T29I ESCs were established by CRISPR/CAS9 technology but needed to have chimera-forming ability and wild-type ESCs to reproduce HP by the BC method. First, the expression of PRSS1 in each tissue was examined using
BioGPS to investigate the influence of PRSS1 mutation on the whole body. As a result, PRSS1 was expressed in the pancreas alone in both human and mouse ( Figure S1 ). Therefore, the PRSS1 mutation would affect only the pancreas.
Second, the gene expression profiles were compared between ESCs to evaluate the chimera-forming ability of PRSS1 T29I ESCs. As a result, the expression of each differentiation marker was similar between PRSS1 T29I ESCs and wild-type ESCs ( Figure 3A) . Furthermore, the gene set enrichment analysis (GSEA) showed that the gene sets involved in both differentiation and stem cells
were not enriched ( Figures 3B and 3C ). The most enriched gene set between PRSS1 T29I and wild-type ESCs was the set involved in DNA polymerase ( Figure   S2 ). The use of CRISPR/CAS9 technology might have affected DNA synthesis, but an enrichment score of 0.57 was not much. Therefore, the PRSS1 T29I would retain its chimera-forming ability.
Reproduction of HP using disease-specific pluripotent stem cells
The Pdx1-null mice that lacked pancreas were dead at two or three days after birth. However, introduction of wild-type ESCs in Pdx1-deficient ESCs was reported to result in the complete rescue of the lethal phenotypes that harbored pancreatic tissues, with 100% contribution of wild-type ESCs. In the field of regenerative medicine, the BC methods have emerged recently organ formation.
Here we applied the BC method for the contribution of disease-specific PRSS1 T29I ESCs and the causative formation of pancreatitis. In this experiment, we injected PRSS1 T29I ESCs into the blastocysts that were derived from Pdx1-null mice and were transferred to another female, in which pregnancy was mimicked by injection of human chorionic gonadotropin (hCG), creating a provisional belly. Although a newborn was successfully delivered, it died 1.5 days after birth ( Figure 4A ).
To study the situation of PRSS1 T29I ESCs-derived from the embryo in the uterus, we decided to sacrifice the pregnant mice on E19.5 days. We were interested to know whether the injected PRSS1 T29I ESCs contributed to the tissues of the pancreas. We performed an anti-Gfp antibody immunostaining experiment on E19.5-day embryos, because the PRSS1 T29I ESCs were labeled by the GFP gene. The results indicated that Gfp-positive cells were detected in the entire pancreas and in the extra-pancreatic organs, such as the liver ( Figure 4B ).
These suggested that the injected PRSS1 T29I ESCs contributed to the formation of chimera. Histologic examination of the embryos derived from the injection of PRSS1 T29I ESCs showed no apparent formation of pancreatic organs ( Figure   4D ), whereas those from wild-type ESCs had formed a pancreas ( Figure 4C ).
Moreover, the liver of PRSS1 T29I -derived embryos showed severely destroyed structures and thin diaphragm ( Figure 5A ), presumably due to the effects of activated trypsin. We then measured the trypsin activity in mice tissues of PRSS1 T29I ESCs-derived and wild-type ESCs-derived embryos. The results indicated that the trypsin activity in PRSS1 T29I ESCs-derived embryos was significantly higher than that in wild-type ESCs-derived embryos ( Figure 5B ).
The present study showed that the BC methods of PRSS1 T29I ESCs can reproduce the phenotype of HP in a model. , based on the fact that the mice died immediately after birth.
A recent report indicated that a 3D human iPS-cell engineered heart tissue was a useful tool for modeling torsade de pointes, which is a lethal arrhythmia that is often drug-induced; in particular, the 3D model provided details on the mechanisms underlying arrhythmia generation and on the means for drug In the present study, we established PRSS1 T29I ESCs. The successful maintenance of the culture of PRSS1 T29I and wild-type ESCs in a medium containing LIF suggested that the PRSS1 T29I ESCs were in the undifferentiated state. Moreover, the gene expression profiles involved in the differentiation and undifferentiation of each ESC were confirmed by RNA-seq to be similar between the ESCs, suggesting that the chimera-formation ability was similar between PRSS1 T29I ESCs and wild-type ESCs. On the other hand, GSEA revealed that the gene set involved in DNA polymerase activity was the most enriched.
Although introduction of a mutant gene by CRISPR/CAS9 might have affected DNA polymerase, the enrichment score was not so high and the PRSS1
T29I
ESCs were maintained in the undifferentiated state. Therefore, we considered that the result of PRSS1 T29I of did not affect the undifferentiated state and chimera-formation ability of PRSS1 T29I ESCs. In other words, establishment of ESCs by Prss1 mutation succeeded without affecting the chimera-formation ability.
We applied the BC method for PRSS1 T29I ESCs to reproduce human HP. In the mice in which the BC method was applied, the PRSS1 T29I ESCs contributed to the formation of the whole pancreas and the chimera. Subsequently, the mice-derived PRSS1 T29I ESCs resulted in activation of trypsin and destroyed liver and lung. These results indicated that the BC method for the PRSS1
ESCs succeeded to reproduce the pathology of human HP ( Figure 6 ). However, the mice died immediately after birth and more severe disease onset than that in human. Further improvement of the BC method is necessary to elucidate disease pathophysiology and drug screening. In present study, BC method was able to reproduce pancreatic disease and is expected to reproduce disease in other organs.
In the present study, we were able to reproduce HP by the BC method. The embryos derived from PRSS1 T29I ESCs, not from wild-type ESCs, showed features of extensive digestion by trypsin in the pancreatic lesion, as well as in the liver and lung of the Pdx1-deficient blastocyst body. This suggested the contribution of the transcription factor Pdx1 in a broad range of organs, which is compatible with the intercross species BC method (Kobayashi et al., 2010) .
Although the application of this method to human cells has ethical issues to be overcome, the use of disease-specific iPS cells would be an attractive tool for the elucidation of disease mechanism and can contribute to the progression of medicine.
Materials and Methods
Protein structure analysis
We created the 3D structures of wild-type (WT) PRSS1 and mutated PRSS1
(human: N29I, mouse: T29I) using the homology modeling method, based on the crystal structure of the human cationic trypsin G193R mutant (PDB ID: 4WWY). Then, the structures of the WT and mutated type were subjected to energy minimization in the water phase of the AMBER force field using the AMBER12 program package. Using these minimized structures, we performed molecular dynamics (MD) simulation to investigate the differences in flexibility between the WT and mutated structures. We performed the MD simulation (i.e., elevated temperature process and thermodynamically conformational sampling)
at around 37 °C (310 K) using the periodic boundary condition. The flexibility of each protein structure was compared by calculating the root mean square deviation (RMSD) from each initial coordinate. Moreover, we created the structures that were exchanged at the 29th amino acid residue in PRSS1 between humans (N→T) and mice (T→N) and compared the original structures with the mutated structures. The RMSD was calculated as an index of structural difference in each minimized structure after in silico annealing processes.
Establishment of a disease-specific iPS model using mouse embryonic stem cell PRSS1 T29I ESCs were generated using using gRNAs in the CRISPR/CAS9 System ( Figure 1A ). On the first day, pregnant male serum gonadotropin (5 IU) was administered intraperitoneally to female Pdx1 KO hetero C57BL/6J mice.
On the third day, human chorionic gonadotropin (5 IU) was administered intraperitoneally to the mice. Subsequently, the mice were mated with male Pdx1 KO hetero C57BL/6J mice. On the sixth day, blastocysts were collected from the female mice and were injected with PRSS1 T29I ESCs. Subsequently, the blastocysts were cultured overnight. On the seventh day, the cultured blastocysts were transplanted into the uteri of the foster mothers.
ESC culture
The v6.5 mouse ES cells, which were derived from a male mouse embryo, were cultured in Dulbecco's modified eagle medium (Nakalai Tesque, Japan) containing 15% FBS (Thermofisher); 1% non-essential amino acids (NakalaiTesque, Japan); 1% sodium pyruvate (Nakalai Tesque, Japan); and LIF (NakalaiTesque, Japan) at 37 °C in a humidified atmosphere with 5% CO 2 .
RNA-seq for ESCs
RNA was extracted from each ESC and was sequenced by Hi-seq2500. Gene expression was analyzed using CLC Genomics Workbench Ver.9.0 and GSEA software.
Immunostaining
Immunohistochemical analysis was performed on 3. Funakoshi, Japan) was used to visualize the antigens. Counter-staining was performed using hematoxylin only or HE.
Trypsin activity assay
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